Skip to content
Review

Eldecalcitol in older adults with kidney vulnerability: a narrative review of risk-based use, dose adjustment, and monitoring

Aug 2026 · Clinical and Experimental Nephrology · Vol 30, pp. 1392 - 1397 · 0 citations · 24 references
Medicine

TL;DR

Safe use of Eldecalcitol requires risk-based selection rather than passive routine-dose prescribing, planned biochemical follow-up, and explicit treatment reassessment, rather than passive routine-dose prescribing and explicit treatment reassessment.

View source

Similar papers

Review

Clinical effectiveness and cost-utility analysis of phosphate binders for treating hyperphosphatemia in end-stage renal disease patients : a multicenter real-world study

Uncontrolled hyperphosphatemia in end-stage renal disease (ESRD) patients increases the risk of cardiovascular disease (CVD), bone disorders, and mortality. Phosphate binders (PBs) are recommended as a treatment option. Calcium-based PBs (CBPBs) had significantly higher all-cause mortality rates compared to non-calcium...

Kamolpat Chaiyakittisopon · 0 citations
Review Open access Sep 2026

Real-world use of pegylated erythropoietin in CKD-related anemia: an Indian modified Delphi consensus

Anemia is a common and clinically significant complication of chronic kidney disease (CKD), contributing to impaired quality of life, increased cardiovascular risk, and higher mortality. Although erythropoiesis-stimulating agents (ESAs) remain the cornerstone of anemia management, conventional short- and intermediate-a...

V. Kher, Jatin Kothari, Jitendra Kumar et al. · 0 citations
Review Open access Sep 2026

Contemporary anticoagulation management across the spectrum of kidney disease: a narrative review and expert Recommendations by Kasralainy Nephrology Group (KANG)

Chronic kidney disease (CKD) presents a significant clinical challenge for anticoagulation therapy due to the coexistence of elevated thromboembolic risk and increased bleeding tendency. Management is further complicated by altered pharmacokinetics, limited high-quality evidence in advanced CKD, and the systematic excl...

A. Soliman, S. El-Khashab, A. Fayed et al. · 0 citations
Review Open access Sep 2026

Effects of denosumab or romosozumab on vascular calcification in dialysis patients: a systematic review and meta-analysis.

INTRODUCTION Patients on hemodialysis are at high risk of vascular calcification, which contributes to cardiovascular events and mortality. The impact of osteoporosis therapies, including denosumab and romosozumab, on vascular calcification in this population remains uncertain. This systematic review and meta-analysis...

Dueanchonnee Sribenjalak, Hyeonmok Kim, P. Ebeling et al. · 0 citations
Review Open access Sep 2026

Anti-resorptive therapy with denosumab in elderly and senile patients with osteoporosis: a narrative review and clinical recommendations

Senile osteoporosis represents one of the most pressing challenges in modern geriatric medicine, characterized by high prevalence, delayed diagnosis, and severe complications such as low-energy fractures, which are associated with disability, loss of independence, and significantly increased mortality. The pathogenetic...

E. Dudinskaya, A. V. Naumov, N. O. Khovasova · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.